New drug combo aims to stop liver cancer in its tracks

NCT ID NCT05366829

Recruiting now Disease control Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the immunotherapy drug tislelizumab after standard liver-directed treatments (like radiation) can help control inoperable liver cancer. About 35 adults with hepatocellular carcinoma who have not had systemic therapy will receive tislelizumab to boost the immune system's response. The study will check for side effects and measure how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tislelizumab (a drug that helps the immune system fight cancer)
What this could lead to: If it works, this could point toward a new treatment option for people with inoperable liver cancer, potentially improving how long they live without the cancer growing.
What could go wrong: This is a small, early-phase trial with only 35 participants. The drug may cause serious side effects, and it is not yet known if it will improve outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR LIVER CELL CARCINOMA

Contacts and locations

Locations

Montefiore Medical Center
RECRUITING

The Bronx, New York, 10451, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.